Jeff Yass’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
Jeff Yass's ELVN Position: Q3 2026 in Review
Jeff Yass increased its Enliven Therapeutics (ELVN) stake by 402% in Q3 2026, buying an estimated $874K and bringing the position to 20,032 shares worth $918K. The position accounts for ﹤0.01% of the portfolio, ranked #8161.
Jeff Yass first reported a position in ELVN in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.12M in Q2 2025. 215 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.
- Jeff Yass held 20,032 shares of Enliven Therapeutics worth $918K as of Q3 2026.
- Jeff Yass bought 16,039 Enliven Therapeutics shares in Q3 2026, an estimated $874K.
- Enliven Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #8161 holding.
- Jeff Yass first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 12 quarters since.
- Jeff Yass's Enliven Therapeutics position peaked at $1.12M in Q2 2025.
- 215 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.
Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.